Serine proteases mediate inflammatory pain in acute pancreatitis
Open Access
- 1 June 2011
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 300 (6) , G1033-G1042
Abstract
Acute pancreatitis is a life-threatening inflammatory disease characterized by abdominal pain of unknown etiology. Trypsin, a key mediator of pancreatitis, causes inflammation and pain by activating protease-activated receptor 2 (PAR2), but the isoforms of trypsin that cause pancreatitis and pancreatic pain are unknown. We hypothesized that human trypsin IV and rat P23, which activate PAR2and are resistant to pancreatic trypsin inhibitors, contribute to pancreatic inflammation and pain. Injections of a subinflammatory dose of exogenous trypsin increased c-Fos immunoreactivity, indicative of spinal nociceptive activation, but did not cause inflammation, as assessed by measuring serum amylase and myeloperoxidase activity and by histology. The same dose of trypsin IV and P23 increased some inflammatory end points and caused a more robust effect on nociception, which was blocked by melagatran, a trypsin inhibitor that also inhibits polypeptide-resistant trypsin isoforms. To determine the contribution of endogenous activation of trypsin and its minor isoforms, recombinant enterokinase (ENK), which activates trypsins in the duodenum, was administered into the pancreas. Intraductal ENK caused nociception and inflammation that were diminished by polypeptide inhibitors, including soybean trypsin inhibitor and a specific trypsin inhibitor (type I-P), and by melagatran. Finally, the secretagogue cerulein induced pancreatic nociceptive activation and nocifensive behavior that were reversed by melagatran. Thus trypsin and its minor isoforms mediate pancreatic pain and inflammation. In particular, the inhibitor-resistant isoforms trypsin IV and P23 may be important in mediating prolonged pancreatic inflammatory pain in pancreatitis. Our results suggest that inhibitors of these isoforms could be novel therapies for pancreatitis pain.Keywords
This publication has 50 references indexed in Scilit:
- Transient receptor potential ion channels V4 and A1 contribute to pancreatitis pain in miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- Transient receptor potential ankyrin-1 has a major role in mediating visceral pain in miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- Protection Against Chronic Pancreatitis and Pancreatic Fibrosis in Mice Overexpressing Pancreatic Secretory Trypsin InhibitorPancreas, 2010
- PAR2 exerts local protection against acute pancreatitis via modulation of MAP kinase and MAP kinase phosphatase signalingAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Protease-activated Receptor-2 Exerts Contrasting Model-specific Effects on Acute Experimental PancreatitisJournal of Biological Chemistry, 2008
- Trypsin IV or Mesotrypsin and p23 Cleave Protease-activated Receptors 1 and 2 to Induce Inflammation and HyperalgesiaJournal of Biological Chemistry, 2007
- The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodentsLife Sciences, 2007
- The role of trypsin, trypsin inhibitor, and trypsin receptor in the onset and aggravation of pancreatitisJournal of Gastroenterology, 2006
- Protection against acute pancreatitis by activation of protease-activated receptor-2American Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
- Cloning of the cDNA encoding human brain trypsinogen and characterization of its productGene, 1993